Samsung Biologics
27F, 1320-10, Seocho 2-dong, Seocho-gu
Seoul
137-965
Tel: 82-2-2255-8500
Fax: 82-2-2255-8577
Website: http://www.samsungbiologics.com/
98 articles with Samsung Biologics
-
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
8/1/2022
GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.
-
Samsung Biologics Reports Second Quarter 2022 Financial Results
7/27/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the second quarter of fiscal year 2022.
-
Samsung Biologics to purchase land for its second Bio Campus
7/18/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced that it has signed a land purchase agreement with the Incheon Free Economic Zone on July 18th to support the build out of its second Bio Campus.
-
'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report
7/11/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, published its second annual ESG Report, reflecting the company's sustainability efforts in 2021 to address a wide range of environmental, social, and governance activities related to its business.
-
Most of Samsung's investment will be in South Korea, and it expects to create 80,000 new jobs through 2026, or about 16,000 positions annually.
-
A recent research report points to the CDMO market heating up. P&S projected the global biologics CDMO market would hit $31.839 million by 2030.
-
Samsung Biologics Reports First Quarter 2022 Financial Results
4/27/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the first quarter of fiscal year 2022.
-
Samsung Biologics completes full acquisition of Samsung Bioepis
4/20/2022
Samsung Biologics announced that it has completed the purchase of Biogen's stake in the Samsung Bioepis joint venture for USD $2.3 billion.
-
Samsung Biologics holds 11th Annual General Meeting of Shareholders
3/29/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, hosted its 11th Annual General Meeting of Shareholders.
-
Samsung Biologics receives 2022 CMO Leadership Award in all six categories
2/7/2022
Samsung Biologics announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science Leader.
-
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
-
Fujifilm announced that it is acquiring Atara Biotherapeutics' cell therapy manufacturing facility in California for $100 million.
-
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
1/24/2022
Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year of 2021.
-
Samsung Biologics Shares Strategic Roadmap for Sustainable Growth at the 40th Annual JP Morgan Healthcare Conference
1/12/2022
Samsung Biologics (KRX: 207940.KS) announced its sustainable growth plan for this year at the 2022 Annual JP Morgan Healthcare Conference.
-
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
12/14/2021
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
-
Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
12/14/2021
Moderna, a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the Ministry of Food and Drug Safety of Korea has issued a marketing authorization for Spikevax®, Moderna's COVID-19 vaccine manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.
-
Samsung Biologics adds to global ISO certifications with Quality Management System
12/7/2021
Samsung Biologics, the world's leading contract development and manufacturing organization, held an award ceremony with the British Standard Institution at its Songdo headquarters for global ISO9001 certification in recognition of the company's Quality Management System.
-
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing
11/24/2021
GreenLight Biosciences and Samsung Biologics announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.
-
Samsung Biologics Reports Third Quarter 2021 Financial Results
10/26/2021
Samsung Biologics, a leading contract development and manufacturing organization, announced record-high financial results for the third quarter of fiscal 2021.
-
Enzolytics Inc. and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies
10/7/2021
Enzolytics Inc. to leverage Samsung Biologics' development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND.